Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpeds.2019.09.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
analysis of lncRNA-miRNA-mRNA signatures related to Sorafenib effectiveness in liver cancer cells.
World J Gastroenterol
January 2025
Department of Oncology Surgery, Cell Therapy and Organ Transplantation, Institute of Biomedicine of Seville, Virgen del Rocio University Hospital, Seville 41013, Spain.
Background: Hepatocellular carcinoma (HCC) is the most common subtype of primary liver cancer with varied incidence and epidemiology worldwide. Sorafenib is still a recommended treatment for a large proportion of patients with advanced HCC. Different patterns of treatment responsiveness have been identified in differentiated hepatoblastoma HepG2 cells and metastatic HCC SNU449 cells.
View Article and Find Full Text PDFThe immunohistochemical combination of low SGLT2 expression and high PRDX4 expression independently predicts shortened survival in patients undergoing surgical resection for hepatoblastoma.
Diagn Pathol
January 2025
Department of Pathology and Laboratory Medicine, Kanazawa Medical University, Ishikawa, 920-0293, Japan.
Background: Hepatoblastoma (HB) is the most common malignant solid tumor of the liver in children and is a fatal disease with a poor prognosis. Therefore, indicators that can be used for the early prediction of the HB prognosis are necessary. Sodium glucose cotransporter 2 (SGLT2) is a glucose transporter protein present in the proximal renal tubules.
View Article and Find Full Text PDFGlobal, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: a trend analysis.
Hepatol Int
November 2024
Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
Background And Purpose: Hepatoblastoma is the most common primary liver cancer in children, yet comprehensive understanding of its epidemiology is limited globally. We aimed to estimate the global trend of hepatoblastoma in children from 1990 to 2021.
Methods: We collected data on hepatoblastoma in children aged 0 to 10 years from 1990 to 2021, derived from Global Burden of Disease (GBD) 2021.
Long-term renal outcomes of children with cancers treated with platinum-based chemotherapy: A retrospective chart analysis.
Pediatr Blood Cancer
January 2025
Department of Nephrology, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
Purpose: Platinum-based chemotherapy is a mainstay of treatment for many childhood cancers but is associated with acute nephrotoxicity and long-term ototoxicity. There is emerging evidence of long-term renal complications. This study aimed to assess the prevalence of chronic kidney disease (CKD) in children treated with platinum chemotherapy (cisplatin and carboplatin) and identify potential risk factors for the development of CKD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!